Abstract: [Subject] To provide laser Doppler blood flow measuring method and device which achieve multi-dimensional measurement efficiently at a high degree of accuracy over a wide range with a simple optical system and device. [Solving Means] Laser light from a semiconductor laser 12 is split and formed into sheet lights Ls using a cylindrical lens 22, and the sheet lights Ls are crossed with each other at a predetermined position. A lens system 30 configured to form an image of scattered lights into a linear shape at a linear irradiation site Lx where the sheet lights Ls cross with each other is provided. An optical fiber array 32 having a plurality of optical fibers 34 is provided at an image-forming position of the lens system 30. Avalanche photodiodes 42 configured to convert the scattered lights which are shifted in frequency by the Doppler effect caused by the blood flow into electric signals for the each optical fiber 34 are provided.

Abstract: The present invention relates to a therapeutic agent for neuropathic pain containing, as an active ingredient, a compound represented by general formula (I) or a pharmacologically acceptable acid addition salt thereof: (wherein R1, R2, R3, R4, R5, R6, R7, R8, A, and B have the same definitions as those described in the specification), and an animal model produced by administering (+)-4a-(3-hydroxyphenyl)-2-methyl-1,2,3,4,4a,5,12,12a-octohydro-trans-quinolino[2,3-g]isoquinoline. The present invention makes it possible to perform drug treatment for neuropathic pain. The therapeutic effect of a compound against neuropathic pain can also be evaluated.

Abstract: A biomarker is provided for an allergic disease caused by an allergic reaction that is caused not exclusively by histamine release, such as pruritus, and use of the same. Use of Granzyme A as a biomarker makes it possible to provide an indication for chronic itching skin disease, for which existing antiallergic drugs have little effect, and easily and adequately allow diagnosis of the disease. It is possible to, for example, make a diagnosis of an allergic disease with an IV type allergy-like reaction not depending on the antigen-antibody reaction system. Screening with the use of Granzyme A enables the development of novel remedies for allergic diseases. Moreover, a drug capable of specifically controlling the action of a granzyme enables treatment of allergic disease with little side effect.

Abstract: [Subject] To provide laser Doppler blood flow measuring method and device which achieve multi-dimensional measurement efficiently at a high degree of accuracy over a wide range with a simple optical system and device. [Solving Means] Laser light from a semiconductor laser 12 is split and formed into sheet lights Ls using a cylindrical lens 22, and the sheet lights Ls are crossed with each other at a predetermined position. A lens system 30 configured to form an image of scattered lights into a linear shape at a linear irradiation site Lx where the sheet lights Ls cross with each other is provided. An optical fiber array 32 having a plurality of optical fibers 34 is provided at an image-forming position of the lens system 30. Avalanche photodiodes 42 configured to convert the scattered lights which are shifted in frequency by the Doppler effect caused by the blood flow into electric signals for the each optical fiber 34 are provided.

Abstract: A biomarker is provided for an allergic disease caused by an allergic reaction that is caused not exclusively by histamine release, such as pruritus, and use of the same. Use of Granzyme A as a biomarker makes it possible to provide an indication for chronic itching skin disease, for which existing antiallergic drugs have little effect, and easily and adequately allow diagnosis of the disease. It is possible to, for example, make a diagnosis of an allergic disease with an IV type allergy-like reaction not depending on the antigen-antibody reaction system. Screening with the use of Granzyme A enables the development of novel remedies for allergic diseases. Moreover, a drug capable of specifically controlling the action of a granzyme enables treatment of allergic disease with little side effect.

Abstract: The present invention relates to a therapeutic agent for neuropathic pain containing, as an active ingredient, a compound represented by general formula (I) or a pharmacologically acceptable acid addition salt thereof: (wherein R1, R2, R3, R4, R5, R6, R7, R8, A, and B have the same definitions as those described in the specification), and an animal model produced by administering (+)-4a-(3-hydroxyphenyl)-2-methyl-1,2,3,4,4a,5,12,12a-octohydro-trans-quinolino[2,3-g]isoquinoline. The present invention makes it possible to perform drug treatment for neuropathic pain. The therapeutic effect of a compound against neuropathic pain can also be evaluated.

Abstract: The object of the present invention is to provide a pharmaceutical composition for treatment of pruritus not associated with dermal inflammation such as pruritus caused by the decrease of cutaneous barrier function. Particularly, the object of the present invention is to provide a pharmaceutical composition, comprising at least one substances having the inhibitory function of NO activity in vivo, such as the inhibitory activity for NO biosynthesis and/or at least one substances having the eliminating activity for NO and a pharmaceutically acceptable carrier.

Abstract: The present invention provides itching model animals usable for evaluating the therapeutic effect of medicines, medicinal compositions, external preparations for the skin, etc. on itching induced by hypofunction of cutaneous barrier and also for evaluating the effect in improving the barrier function of the skin weakened and converted to be itchy by an external preparation for the skin or a cosmetic. The present invention also provides a method for producing such animals.